The European Commission (EC) has granted exceptional marketing authorization for NEZGLYAL® (leriglitazone), marking the first pharmacological treatment for childhood cerebral adrenoleukodystrophy (cALD) in the EU. This therapy, aimed at male patients aged 2-12 years with Gadolinium (Gd)-negative brain lesions, offers a crucial non-invasive option to halt the rapid progression of this debilitating neurodegenerative condition, which can lead to severe neurological decline and death.
The approval is based on findings from the Phase 2/3 NEXUS1 study, alongside real-world evidence collected from compassionate use programs. Dr. Caroline Sevin highlighted the importance of early intervention in cALD, emphasizing the limitations of current invasive options like hematopoietic stem cell transplantation, which depend on donor availability and must occur within a narrow treatment window.
The drug, administered orally daily, is expected to launch in Germany by the end of the year, with further introductions planned throughout Europe pending national reimbursement negotiations. The significance of this development lies not only in its potential to improve patient outcomes and quality of life but also in addressing an unmet clinical need within the cALD community.
Moreover, ongoing research, including the CALYX2 and TREE3 trials, aims to explore the drug’s effectiveness in adult patients and in those with Rett syndrome, respectively. The approval reflects years of collaborative research and is viewed as a transformative step for clinicians, policymakers, and patient organizations advocating for innovative treatments in rare diseases.
Source: www.news-medical.net
